

Appl. No. : 09/558,576  
Filed : April 26, 2000

Specifically, Example 9 states, at page 28 lines 17-20:

*Three or more doses of 2.9 µg SP-D given at 24 hour intervals decreased both alveolar and saturated PC pools (see Figure 14). This dose of SP-D given is approximately the amount present in the endogenous pool in SP-D(+/+) mice. Given the lung association and clearance kinetics, this is a low dose.*

Further support for the amendment can be found in the specification as follows:

Page 20, lines 17 – 19:

*"The present findings are consistent with an important and unanticipated role of SP-D in the modulation of pulmonary inflammation..."*

Page 31, lines 8 -- 14:

***"Involvement of SP-D in Pulmonary Infection***

*... SP-A and SP-D have specific interactions with various microorganisms in vitro, modifying pulmonary inflammation in vitro by altering cytokine and free radical production. The role of SP-D in bacterial clearance and inflammatory response of the lung was evaluated in vivo using a mouse model of SP-D deficiency."*

Page 33, lines 13 – 15:

*"These findings demonstrate that SP-D plays an important role in innate defense and regulation of inflammation in the lung after RSV infection in vivo. Similar findings were observed after Influenza and adenovirus infected the lung."*

In light of the above amendments and remarks, reconsideration and withdrawal of the outstanding rejections is specifically requested. The specific changes to the amended claim are shown on a separate set of pages attached hereto and entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment. On this set of pages, the insertions are double underlined while the ~~deletions are stricken through~~.

Appl. No. : 09/558,576  
Filed : April 26, 2000

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 20 Nov 2002

By: 

Dale C. Hunt, Ph.D.  
Registration No. 41,857  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

Appl. No. : 09/558,576  
Filed : April 26, 2000

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS:**

10. (Amended) A pharmaceutical composition ~~effective in reducing pulmonary inflammation in mammals comprising:~~ isolated, purified, or recombinant SP-D protein in an amount sufficient to reduce pulmonary inflammation in mammals, the composition further comprising ~~admixture with~~ a pharmaceutically acceptable excipient.

S:\DOCS\SGJ\SGJ-2135.DOC:gml12002